Company profile: Double Bond Pharmaceutical
1.1 - Company Overview
Company description
- Provider of first-in-class pharmaceutical therapies and drug delivery solutions for cancers, infections, autoimmune diseases and other life-threatening disorders. Offers the BeloGal biomimetic encapsulation platform and pipeline candidates including SI-053 for brain cancer, SA-033 targeting doxorubicin to the liver, and Belopenem directing meropenem to infected lungs.
Products and services
- BeloGal: Engineers a drug-delivery system using biomimetic encapsulation of active pharmaceutical ingredients to increase therapeutic effect and protect healthy tissues via targeted organ delivery
- SI-053: Produces a temozolomide gel locally administered into the cavity created after glioblastoma resection to treat brain cancer, concentrating therapy at the post-surgical site
- SA-033: Creates a liver-targeted treatment for liver cancer using BeloGal technology to direct doxorubicin directly to the liver, achieving organ-specific administration.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Double Bond Pharmaceutical
Biocoat
HQ: United States
Website
- Description: Provider of custom-engineered biomaterial coatings for medical devices, specializing in lubricious hydrophilic coatings that deliver lubricity, durability, and low particulate counts. Services include contract coating, custom polymer synthesis, and reagent fulfillment, with specialized hydrophilic solutions for neurovascular and cardiovascular devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocoat company profile →
Gatan
HQ: United States
Website
- Description: Provider of instrumentation and software that enhance and extend electron microscopes, compatible with all brands and spanning the workflow from specimen preparation and manipulation to imaging and analysis. Products include GIF Quantum ER for energy-filtered imaging and EELS, K2 Summit cryo-EM camera, Monarc Pro T for optically coupled TEM, ClearView TEM camera, DigitalMicrograph software, and service plans.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Gatan company profile →
Applied BioCode
HQ: United States
Website
- Description: Provider of multiplex molecular diagnostic systems and panels for clinical testing, life science research, medicine, and AgBio. Offerings include the BioCode® MDx-3000 automated, high-throughput system and assays such as the BioCode® Gastrointestinal and Respiratory Pathogen Panels, BioCode® STI + Resistance Panel, BioCode® CoV-2 Flu Plus Assay, and BioCode® SARS-CoV-2 Assay.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Applied BioCode company profile →
Bruker
HQ: United States
Website
- Description: Provider of analytical and medical instruments covering NMR, ESR, FT-IR and X-ray spectroscopy. MALDI Imaging to visualize molecular distribution in tissue sections; neofleX MALDI-TOF/TOF benchtop MS for protein and peptide analysis; Q6 NEWTON optical emission spectrometer for precise metal and alloy composition; BEAM FT-NIR for real-time process control of solid and semi-solid materials; and Dektak Pro profilometer for semiconductor surfaces.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bruker company profile →
B-MoGen
HQ: United States
Website
- Description: Provider of genome engineering solutions, including the TcBuster Transposon System, a non-viral genetic modification method for delivering therapeutic payloads to diverse cell types, enabling rapid transgenic mammalian cell generation, multigene transfer, and CRISPR-mediated knockouts; and ScaleReady, a partnership that reduces complexity and cost in immune cell therapy and supports scalable immune cell expansion with platform, process, and product continuity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full B-MoGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Double Bond Pharmaceutical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Double Bond Pharmaceutical
2.2 - Growth funds investing in similar companies to Double Bond Pharmaceutical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Double Bond Pharmaceutical
4.2 - Public trading comparable groups for Double Bond Pharmaceutical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →